PNC FINANCIAL SERVICES GROUP, INC. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
PNC FINANCIAL SERVICES GROUP, INC. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$309,015
+109.7%
6,808
+159.4%
0.00%
Q2 2023$147,368
+28.9%
2,625
+3.8%
0.00%
Q1 2023$114,341
-0.5%
2,528
-10.6%
0.00%
Q4 2022$114,958
-40.7%
2,828
-4.3%
0.00%
Q3 2022$194,000
+12.8%
2,954
+4.5%
0.00%
Q2 2022$172,000
-9.0%
2,828
-6.2%
0.00%
Q1 2022$189,000
-80.3%
3,016
-76.2%
0.00%
-100.0%
Q4 2021$960,000
-35.0%
12,677
-3.9%
0.00%0.0%
Q3 2021$1,478,000
-29.6%
13,195
+1.7%
0.00%
-50.0%
Q2 2021$2,100,000
+28.2%
12,976
-3.5%
0.00%0.0%
Q1 2021$1,638,000
-15.1%
13,441
+6.6%
0.00%0.0%
Q4 2020$1,930,000
+100.8%
12,603
+9.6%
0.00%
+100.0%
Q3 2020$961,000
+20.4%
11,500
+5.9%
0.00%0.0%
Q2 2020$798,000
-10.1%
10,860
-48.2%
0.00%0.0%
Q1 2020$888,000
-29.1%
20,960
+1.9%
0.00%0.0%
Q4 2019$1,252,000
+46.4%
20,560
-1.4%
0.00%0.0%
Q3 2019$855,000
-16.2%
20,846
-3.7%
0.00%0.0%
Q2 2019$1,020,000
+31.8%
21,6460.0%0.00%0.0%
Q1 2019$774,000
+25.6%
21,646
+0.3%
0.00%0.0%
Q4 2018$616,000
+142.5%
21,586
+277.5%
0.00%
Q3 2018$254,000
-56.3%
5,718
-42.2%
0.00%
-100.0%
Q2 2018$581,0009,8940.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders